Comparative Pharmacology
Head-to-head clinical analysis: CECLOR versus CEFOBID IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR versus CEFOBID IN PLASTIC CONTAINER.
CECLOR vs CEFOBID IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It exhibits bactericidal activity against susceptible organisms.
Cefoperazone, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
250 mg orally every 8 hours; for severe infections, 500 mg orally every 8 hours.
2 g IV every 8-12 hours; usual total daily dose 4-6 g, severe infections up to 12 g daily divided q8h.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.9 hours in adults with normal renal function. Prolonged to 2-3 hours in end-stage renal disease. Half-life does not increase significantly with hepatic impairment.
2.2 hours (normal renal function); prolonged to 4-5 hours in elderly or hepatic impairment; in severe renal failure (CrCl <10 mL/min), may extend up to 8 hours.
Primarily renal: 80-90% of unchanged drug excreted by glomerular filtration and tubular secretion within 8 hours. Biliary excretion accounts for <5%; fecal elimination negligible.
Renal: 65-85% unchanged; biliary: 10-20% (fecal elimination); total renal clearance approximates glomerular filtration rate.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic